Coeptis Therapeutics Holdings, Inc. (COEP) Stock Grade

About Coeptis Therapeutics Holdings, Inc.'s fundamentals

Coeptis Therapeutics is a small-cap biotechnology company with a market capitalization of $60.3 million that reported zero year-over-year revenue growth. The company posted a significant net loss in its latest annual statement, resulting in a net margin of -874.3%, indicating it is currently unprofitable and spending substantially more than it generates in revenue. With no dividend yield and typical pre-commercial biotech financials, the company's valuation metrics like P/E ratio and return on equity are not meaningful at this stage.